Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?
-
Published:2024-09
Issue:6
Volume:25
Page:e262-e267
-
ISSN:1525-7304
-
Container-title:Clinical Lung Cancer
-
language:en
-
Short-container-title:Clinical Lung Cancer
Author:
Muscolino Paola,
Scimone Claudia,
Sapuppo Elena,
Micali Vincenzo,
Vasta Ignazio,
Santacaterina Anna,
Santarpia Mariacarmela,
Russo AlessandroORCID
Reference25 articles.
1. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020
2. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC;Planchard;N Engl J Med,2023
3. LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a phase III, global, randomized, controlled trial;Cho;Ann Oncol,2023
4. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer;Leonetti;Br J Cancer,2019
5. Genomic landscape of primary resistance to osimertinib among Hispanic patients with EGFR-mutant non-small cell lung cancer (NSCLC): results of an observational longitudinal cohort study;Chamorro;Target Oncol,2023